The concentrated insider buying at $16 suggests management sees material upside. Monitor for upcoming clinical trial readouts or partnership announcements. The absence of CEO open-market purchases is notable but offset by the large director buy and CFO participation.
Price Chart
Executive Summary
Multiple insiders at BlossomHill Therapeutics made significant open-market purchases totaling ~$5.18M, led by director/10% owner Chen Bihua's $5M buy at $16/share. This cluster of insider buying, including the CFO and General Counsel, signals strong confidence in the company's prospects, likely ahead of upcoming pipeline catalysts.
Key Financial Metrics
Key Facts
- Total open-market purchases of ~$5.18M by 4 insiders (Chen Bihua, Schmid John P., Keyes Jason A., Liptak Vincent Paul) over a 7-day window.
- Director/10% owner Chen Bihua purchased 312,500 shares for $5M at $16/share.
- CFO Keyes Jason A. purchased 700 shares for $11,200; General Counsel Liptak purchased ~4,700 shares for ~$75K; Director Schmid purchased 6,000 shares for $96K.
- Multiple executives (Chairman, CEO, GC, Director) also converted derivatives (non-cash) on the same day, indicating ongoing equity compensation and alignment.
Financial Impact
Total open-market purchases of approximately $5.18M by four insiders, including a $5M purchase by a director/10% owner.
Risk Factors
- Biotech development risk; no approved products or revenue.
- Cash burn and potential future dilution.
- Insider buying does not guarantee near-term catalysts or stock performance.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BLSM-1786402935757 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $16.39 (+23.20%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $16.39 (+36.32%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $16.39 (−36.32%) |
Sep 15, 2026 6w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $16.39 (−26.07%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $16.39 (+0.24%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.39 (−0.79%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.39 (−0.79%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $16.39 (+2.50%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.39 (+2.44%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.39 (+2.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers